Search results for "PORIN"

showing 10 items of 260 documents

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

2019

Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentAnti-Inflammatory AgentsDermatologySeverity of Illness IndexSocial lifeYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDisease severityQuality of lifeSurveys and QuestionnairesPsoriasisInternal medicinesystemic therapiesUstekinumabmedicineHumansPsoriasisPatient complianceAgedRetrospective StudiesSkinpsoriasiAged 80 and overTherapeutic regimenbusiness.industryBiologic therapiesAdalimumabGeneral MedicineMiddle Agedmedicine.diseasehumanitiesBiological TherapyTreatment Outcomequality of life030220 oncology & carcinogenesisCyclosporineFemaleUstekinumabDermatologic AgentsbusinessFollow-Up Studiesmedicine.drug
researchProduct

A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine

2005

In this randomized trial renal transplant recipients were treated with basiliximab, everolimus 3 mg/day, low-dose CsA. At transplantation, patients were randomized to stop steroids at the seventh day (group A) or to continue oral steroids in low doses (group B). Of the 113 patients enrolled, 65 were randomized to group A and 68 to group B. All patients were followed for 2 years. During the study 28 (43%) group A patients required reintroduced corticosteroids. One patient died, in group B. The Graft survival rate was 97% in group A and 90% in group B. There were more biopsy-proven rejections in group A (32% vs 16%; P = .044). The mean creatinine clearance was 54 +/- 21 mL/min in group A vs 5…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentBasiliximabUrologyRenal functionGroup AGroup Blaw.inventionRandomized controlled triallawAdrenal Cortex HormonesHLA AntigensmedicineLiving DonorsHumansEverolimuscyclosporineAgedSirolimusTransplantationEverolimusbusiness.industryHistocompatibility TestingeverolimuMiddle Agedrenal transplantationKidney TransplantationSurgerySteroid Avoidance in Renal Transplant PatientsTransplantationRegimentrial; transplant; immunosoppressivesteroid avoidanceSurgeryFemalebusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studies
researchProduct

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell glo…

2011

Abstract Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the contr…

AdultMalemedicine.medical_specialtyTime FactorsTransplantation ConditioningAdolescentmedicine.medical_treatmentImmunologyMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationBiochemistryGastroenterologyDisease-Free Survivallaw.inventionRandomized controlled triallawRecurrenceInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceSurvival rateAntilymphocyte SerumImmunosuppression Therapybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationSurvival RateGraft-versus-host diseaseMethotrexateHematologic NeoplasmsChronic DiseaseCyclosporineFemalebusinessImmunosuppressive AgentsBlood
researchProduct

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated don…

2009

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Anti-T-cell globulins (ATGs) might lower the incidence of GVHD. We did a prospective, randomised, multicentre, open-label, phase 3 trial to compare standard GVHD prophylaxis with ciclosporin and methotrexate with or without anti-Jurkat ATG-Fresenius (ATG-F).Between May 26, 2003, and Feb 8, 2007, 202 patients with haematological malignancies were centrally randomly assigned using computer-generated centre-stratified block randomisation between treatment groups receiving ciclosporin and methotrexate with or without additional ATG-F. One patie…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentT-LymphocytesGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterologyInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceProspective StudiesAntilymphocyte Serumbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationMiddle AgedCiclosporinmedicine.diseaseSurvival AnalysisAnti-thymocyte globulinSurgeryTransplantationGraft-versus-host diseaseMethotrexateOncologyHematologic NeoplasmsCyclosporineRegression AnalysisDrug Therapy CombinationFemaleTransplantation ConditioningbusinessImmunosuppressive Agentsmedicine.drugThe Lancet. Oncology
researchProduct

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

2011

To evaluate adalimumab therapy in refractory uveitis.Prospective case series.A total of 131 patients with refractory uveitis and intolerance or failure to respond to prednisone and at least 1 other systemic immunosuppressive drug participated.Patients received a 40 mg adalimumab subcutaneous injection every other week for 6 months. The associated immunosuppressants were tapered after administering 3 adalimumab injections (week 6).Degree of anterior and posterior chamber inflammation (Standardization of Uveitis Nomenclature Working Group criteria), immunosuppression load (as defined by Nussenblatt et al), visual acuity (logarithm of the minimal angle of resolution [logMAR]), and macular thic…

AdultMalemedicine.medical_specialtyVisual acuityAdolescentInjections SubcutaneousAnti-Inflammatory AgentsDrug ResistanceVisual AcuityArthritisAntibodies Monoclonal HumanizedUveitisRefractoryPrednisoneInternal medicineAdalimumabMedicineHumansMacula LuteaProspective StudiesPars PlanitisProspective cohort studyChildGlucocorticoidsbusiness.industryTumor Necrosis Factor-alphaAdalimumabOff-Label Usemedicine.diseaseSurgeryOphthalmologyMethotrexateTreatment OutcomeChild PreschoolCyclosporineFemalemedicine.symptombusinessUveitisTomography Optical Coherencemedicine.drugOphthalmology
researchProduct

Ciclosporin and thyroid-stimulating immunoglobulins in endocrine orbitopathy.

1989

The study investigated whether ciclosporin (C) affected the thyroid-stimulating immunoglobulins (TSI) in serum of patients with endocrine orbitopathy (EO). The effect of C was compared with that of prednisone (P). Fifteen patients with EO classes III-V received C (n = 7) or P (n = 8). In addition to the immunosuppressants, five patients with Graves' disease in each group received methimazole (MMI). The stimulation of the cAMP levels in the medium of thyrocyte cultures was determined as a parameter of TSI. The TSI levels were markedly lowered in both groups during and after therapy. C group: before therapy 6.2 pmol/ml +/- 1.63 (100%, mean +/- SEM), during treatment 4.6 pmol/ml +/- 2.28 (74%)…

AdultMalemedicine.medical_specialtymedicine.drug_classGraves' diseasemedicine.medical_treatmentThyroid GlandCyclosporinsPrednisoneInternal medicinemedicineCyclic AMPExophthalmosHumansAgedChemotherapyTriiodothyronineMethimazolebusiness.industryThyroidGeneral MedicineMiddle Agedmedicine.diseaseCiclosporinGraves DiseaseTiterEndocrinologymedicine.anatomical_structureImmunoglobulin GCorticosteroidPrednisoneTriiodothyronineFemalebusinessmedicine.drugImmunoglobulins Thyroid-StimulatingResearch in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie
researchProduct

Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational stu…

2011

Introduction: About 30-40% of patients with acute severe ulcerative colitis (UC) fail to respond to intensive intravenous (iv) corticosteroid treatment. Iv cyclosporine and infliximab are an effective rescue therapy in steroid-refractory UC patients but up to now it is still unclear which is the best therapeutic choice. Methods: We reviewed our series of severe steroid-refractory colitis admitted consecutively since 1994 comparing two historical cohort treated with iv cyclosporine (2 mg/kg) or iv infliximab (5 mg/kg). The main outcome was the colectomy rate at 3 months, 12 months and at the end of the follow-up. Results: A total of 65 patients were included: 35 in the cyclosporine group and…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAnti-Inflammatory AgentsAzathioprineKaplan-Meier EstimateGastroenterologyCohort StudiesRefractoryInternal medicinemedicineHumansColitisColectomyRetrospective StudiesColectomybiologybusiness.industryC-reactive proteinGastroenterologyAntibodies MonoclonalRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUlcerative colitisInfliximabInfliximabSurgeryLogistic ModelsTreatment OutcomeCyclosporinebiology.proteinColitis UlcerativeFemalebusinessImmunosuppressive AgentsFollow-Up Studiesmedicine.drugJournal of Crohn's and Colitis
researchProduct

Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis.

2006

Although cyclosporin is effective in immunosuppression following organ transplantation and in the treatment of psoriasis, its use is limited by its side-effects, notably impaired renal function and hypertension. As SDZ IMM 125, a new derivative of the cyclosporin family, showed considerable immunosuppressive activity in experimental studies, with less effect on renal function, it was considered a potential successor to cyclosporin for both indications. In this multicentre, double-blind, placebo-controlled study, the efficacy and tolerability of 40, 100, 200 and 400 mg SDZ IMM 125 daily were studied in 59 patients with psoriasis. Patients were followed for a period of 5 weeks (4 weeks treatm…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentRenal functionCyclosporinsDermatologyPharmacologyGastroenterologyDrug Administration ScheduleDouble-Blind MethodInternal medicinePsoriasismedicineHumansPsoriasisAdverse effectBody surface areaChemotherapyDose-Response Relationship Drugbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseTolerabilityToxicityFemalebusinessImmunosuppressive AgentsFollow-Up StudiesThe British journal of dermatology
researchProduct

Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.

2013

Paraneoplastic myelitis is a rare inflammatory disorder most frequently associated with solid tumors or lymphoproliferative disorders. Patients often harbor onconeuronal antibodies and their prognosis is usually poor. Here we report a 42-year old woman with longitudinally extensive transverse myelitis and aquaporin-4 (AQP4) antibodies that led to the diagnosis of ovarian teratoma. After tumor removal and immune therapy (including corticosteroids, plasma exchange, intravenous immunoglobulins and rituximab) the patient progressively improved achieving complete recovery. Histological study of the teratoma demonstrated neural tissue containing AQP4 expressing cells and intense inflammatory infi…

AdultPathologymedicine.medical_specialtyImmunologyLymphoproliferative disordersMyelitis TransverseAutoimmune diseases Paraneoplastic syndrome Transverse myelitisTransverse myelitisDiagnosis DifferentialmedicineImmunology and AllergyHumansNeurociènciesOvarian TeratomaAutoantibodiesAquaporin 4Ovarian Neoplasmsbiologybusiness.industryParaneoplastic MyelitisTeratomamedicine.diseaseNeurologybiology.proteinRituximabFemaleSistema nerviós MalaltiesNeurology (clinical)TeratomaAntibodybusinessBiomarkersmedicine.drugInflammatory disorder
researchProduct

Influence of nifedipine on the metabolism of gingival fibroblasts.

1994

Calcium antagonists are the gold standard in the therapy of coronary heart disease and hypertension. The prototype of these drugs is nifedipine which, as well as its therapeutic effects on the cells of the cardiovascular system, also has unpleasant side effects on other organ systems. One side effect can be a missive hyperplasia of the gingiva, the reason for which are unclear. In vitro experiments were designed to elucidate the influence of nifedipine on the growth of human gingival fibroblasts in short and long term (72 hours, 6 weeks) cell culture. The following cellular parameters were determined quantitatively: cell proliferation (cell count, [3H]thymidine incorporation), protein synth…

AdultSide effectNifedipineCell SurvivalCellGingivaPharmacologyBiochemistrychemistry.chemical_compoundNifedipineCyclosporin aLactate dehydrogenasemedicineHumansCells CulturedDose-Response Relationship DrugChemistryCell growthDNAHyperplasiaFibroblastsmedicine.diseaseChromatography Ion Exchangemedicine.anatomical_structureCell cultureProtein BiosynthesisProteoglycansCell Divisionmedicine.drugBiological chemistry Hoppe-Seyler
researchProduct